Edgewise Therapeutics (NASDAQ:EWTX) Upgraded at Wall Street Zen

Posted by Geri Gentry on Oct 7th, 2026

Wall Street Zen upgraded shares of Edgewise Therapeutics (NASDAQ:EWTX – Free Report) from a sell rating to a hold rating in a research note released on Sunday morning,Wall Street Zen reports.

EWTX has been the topic of a number of other reports. JPMorgan Chase & Co. lifted their price target on Edgewise Therapeutics from $53.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Oppenheimer initiated coverage on Edgewise Therapeutics in a research note on Thursday, July 9th. They set an “outperform” rating and a $51.00 price objective for the company. HC Wainwright raised their target price on shares of Edgewise Therapeutics from $45.00 to $57.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Royal Bank Of Canada lifted their target price on shares of Edgewise Therapeutics from $48.00 to $59.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 17th. Finally, Evercore reiterated an “outperform” rating and set a $55.00 price target on shares of Edgewise Therapeutics in a report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $51.33.

Check Out Our Latest Stock Report on Edgewise Therapeutics

Edgewise Therapeutics Trading Down 0.7%

Shares of NASDAQ:EWTX opened at $40.02 on Friday. The stock has a market capitalization of $4.35 billion, a P/E ratio of -21.63 and a beta of 0.35. The stock’s 50-day moving average price is $42.89 and its 200-day moving average price is $38.16. Edgewise Therapeutics has a 12-month low of $14.25 and a 12-month high of $48.51.

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). As a group, research analysts predict that Edgewise Therapeutics will post -2.09 EPS for the current year.

Insider Activity at Edgewise Therapeutics

In other Edgewise Therapeutics news, insider Alan Russell sold 5,901 shares of Edgewise Therapeutics stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $43.73, for a total transaction of $258,050.73. Following the sale, the insider directly owned 31,466 shares of the company’s stock, valued at approximately $1,376,008.18. The trade was a 15.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Kevin Koch sold 17,971 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $43.68, for a total value of $784,973.28. Following the transaction, the chief executive officer owned 52,488 shares in the company, valued at $2,292,675.84. This trade represents a 25.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 38,329 shares of company stock valued at $1,675,529. 21.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Edgewise Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC purchased a new stake in shares of Edgewise Therapeutics in the 2nd quarter worth about $3,723,000. Janus Henderson Group PLC increased its stake in shares of Edgewise Therapeutics by 29.5% in the 1st quarter. Janus Henderson Group PLC now owns 5,915,556 shares of the company’s stock worth $186,289,000 after acquiring an additional 1,348,706 shares in the last quarter. Persistent Asset Partners Ltd purchased a new position in Edgewise Therapeutics during the 2nd quarter valued at about $2,821,000. California State Teachers Retirement System lifted its position in Edgewise Therapeutics by 45.7% during the 1st quarter. California State Teachers Retirement System now owns 73,419 shares of the company’s stock valued at $2,313,000 after acquiring an additional 23,027 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new stake in Edgewise Therapeutics during the second quarter worth about $1,656,000.

About Edgewise Therapeutics

(Get Free Report)

Edgewise Therapeutics, Inc is a biopharmaceutical company focused on developing small-molecule therapies for severe neuromuscular and cardiovascular diseases. The company’s research is centered on muscle biology, with the goal of developing treatments that address the underlying mechanisms of muscle damage and dysfunction.

Edgewise’s lead investigational product is sevasemten, formerly known as EDG-5506, a selective fast skeletal muscle myosin inhibitor being developed for dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy.